Long Ebola Outbreak According To The Government Health Ministry

As the congo’s year long Ebola outbreak has spreading to a new province; with the two cases, including one death, confirming, according to the government health ministry. So the head of the Congo’s Ebola response saying an another vaccine will be using to fight the outbreak; that has killing more than 1,800 people in a year.

The movement of the potentially deadly disease to a new province highlights the difficulties; world health organization has recommending the use of a preventative vaccine manufacturing by Johnson and Johnson. Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a rare but severe, often fatal illness in humans.

As muyembe also promising to put an end to the Ebola outbreak in the next four months. Vaccines to protect against Ebola are under development; and have been using to help control the spread of Ebola outbreaks in Guinea and in the Democratic Republic of the Congo (DRC). Early supportive care with rehydration, symptomatic treatment improves survival.

Government health ministry

There is no licensed treatment proven to neutralize the virus but a range of blood; immunological and drug therapies are under development. Health officials have already vaccinated more than 197,000 people. Two new patients tested positive in the Mwenga area of South Kivu; adding to North Kivu and Ituri provinces where there are confirmed cases of the disease, according to the health ministry.

The Ebola outbreak in eastern Congo has killed 1,808 people out of 2,765 confirmed cases, according to the new report. The current outbreak, which started on Aug. 1 last year, is the second largest in history. USAID head Mark Green visited Congo on Monday and promised that the organization and others will continue to work to end Ebola and invest in medicines and community development.

Experimental Ebola vaccine

But an experimental Ebola vaccine proved highly protective against EVD in a major trial in Guinea in 2015. The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11 841 people. Among 5837 people who receiving the vaccine; no Ebola cases were recording 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine.

However, response efforts have been hampering by attacks on health workers; and continuing mistrust among the affected communities. But community engagement is key to successfully controlling outbreaks. Raising awareness of risk factors for Ebola infection and protective measures (including vaccination) that individuals can take is an effective way to reduce human transmission. Risk reduction messaging should focus on several factors.